Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain
- PMID: 20602712
- DOI: 10.1111/j.1533-2500.2010.00397.x
Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain
Abstract
Background: Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ-opioid receptor agonism and norepinephrine reuptake inhibition. This randomized, open-label phase 3 study (ClinicalTrials.gov Identifier: NCT00361504) assessed the long-term safety and tolerability of tapentadol extended release (ER) in patients with chronic knee or hip osteoarthritis pain or low back pain.
Methods: Patients were randomized 4:1 to receive controlled, adjustable, oral, twice-daily doses of tapentadol ER (100 to 250 mg) or oxycodone HCl controlled release (CR; 20 to 50 mg) for up to 1 year. Efficacy evaluations included assessments at each study visit of average pain intensity (11-point numerical rating scale) over the preceding 24 hours. Treatment-emergent adverse events (TEAEs) and discontinuations were monitored throughout the study.
Results: A total of 1,117 patients received at least 1 dose of study drug. Mean (standard error) pain intensity scores in the tapentadol ER and oxycodone CR groups, respectively, were 7.6 (0.05) and 7.6 (0.11) at baseline and decreased to 4.4 (0.09) and 4.5 (0.17) at endpoint. The overall incidence of TEAEs was 85.7% in the tapentadol ER group and 90.6% in the oxycodone CR group. In the tapentadol ER and oxycodone CR groups, respectively, TEAEs led to discontinuation in 22.1% and 36.8% of patients; gastrointestinal TEAEs led to discontinuation in 8.6% and 21.5% of patients.
Conclusion: Tapentadol ER (100 to 250 mg bid) was associated with better gastrointestinal tolerability than oxycodone HCl CR (20 to 50 mg bid) and provided sustainable relief of moderate to severe chronic knee or hip osteoarthritis or low back pain for up to 1 year.
© 2010 World Institute of Pain.
Similar articles
-
Efficacy of tapentadol ER for managing moderate to severe chronic pain.Pain Physician. 2013 Jan;16(1):27-40. Pain Physician. 2013. PMID: 23340531 Review.
-
Dose conversion between tapentadol immediate and extended release for low back pain.Pain Physician. 2010 Jan-Feb;13(1):61-70. Pain Physician. 2010. PMID: 20119464 Clinical Trial.
-
Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain.Pain Med. 2011 May;12(5):755-60. doi: 10.1111/j.1526-4637.2011.01100.x. Epub 2011 Apr 11. Pain Med. 2011. PMID: 21481168 Clinical Trial.
-
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain.Adv Ther. 2010 Jun;27(6):381-99. doi: 10.1007/s12325-010-0036-3. Epub 2010 Jun 11. Adv Ther. 2010. PMID: 20556560
-
Tapentadol hydrochloride: a centrally acting oral analgesic.Clin Ther. 2009 Dec;31(12):2804-18. doi: 10.1016/j.clinthera.2009.12.003. Clin Ther. 2009. PMID: 20110020 Review.
Cited by
-
Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.Cureus. 2022 Jun 16;14(6):e26000. doi: 10.7759/cureus.26000. eCollection 2022 Jun. Cureus. 2022. PMID: 35855248 Free PMC article. Review.
-
Prescribing trend of tapentadol in a Sydney local health district.Br J Clin Pharmacol. 2022 Sep;88(9):3929-3935. doi: 10.1111/bcp.15448. Epub 2022 Jul 7. Br J Clin Pharmacol. 2022. PMID: 35763675 Free PMC article.
-
Misinterpretation of the "Overdose Crisis" Continues to Fuel Misunderstanding of the Role of Prescription Opioids.J Pain Res. 2022 Apr 5;15:949-958. doi: 10.2147/JPR.S367753. eCollection 2022. J Pain Res. 2022. PMID: 35414752 Free PMC article. No abstract available.
-
An Updated Overview of Low Back Pain Management.Asian Spine J. 2022 Dec;16(6):968-982. doi: 10.31616/asj.2021.0371. Epub 2021 Dec 30. Asian Spine J. 2022. PMID: 34963043 Free PMC article.
-
Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data.Pain Res Manag. 2020 Apr 14;2020:5759265. doi: 10.1155/2020/5759265. eCollection 2020. Pain Res Manag. 2020. PMID: 32351639 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical